NEC Orchestrating Future Fund has significantly invested in Aetion, a U.S.-based provider of healthcare analytics platforms, to foster a groundbreaking partnership aimed at enhancing the Real World Data (RWD) and Real World Evidence (RWE) business, particularly in drug development. This collaboration seeks to address the pressing need for assessing the safety and efficacy of drugs through extensive and large-scale data analysis. As the demand for effective medical interventions grows, leveraging RWD and RWE becomes crucial in bridging the gap between clinical trials and real-world applications.
Addressing Challenges in Drug Development
The use of Real World Data (RWD) and Real World Evidence (RWE) has become more widespread in the medical field, driven by the necessity to evaluate medical interventions’ real-world performance. Despite their potential, harnessing RWD and RWE involves several challenges, including issues related to data collection, standardization of data quality, and ensuring regulatory compliance. In response, Aetion has developed the Aetion Evidence Platform® (AEP), designed to address these challenges. This platform offers standardized, quality-assured, and transparent RWD analysis, making it a vital tool for stakeholders in the healthcare industry.
AEP has become an essential resource for pharmaceutical companies, regulatory authorities, insurers, and healthcare institutions worldwide. It uses scientifically validated methods to transform disparate RWD into reliable RWE, thus supporting effective decision-making processes. Through AEP, users can systematically address the core issues of RWD/RWE usage, ensuring that data collected from various sources are accurate and reliable. This transformative approach significantly improves the drug development process, making it more efficient and effective in bringing new therapies to market.
NEC’s Vision and Strategic Goals
NEC aims to address medical and healthcare challenges through its robust healthcare and life sciences business, which includes electronic medical records (EMRs). By integrating NEC’s technological capabilities with Aetion’s proven expertise in evaluating pharmaceuticals’ safety and efficacy, the partnership aspires to streamline the drug development process. This strategic collaboration will not only enhance the efficiency of drug development but also pave the way for innovative treatment methodologies and personalized medicine.
The NEC Orchestrating Future Fund plays a pivotal role in this vision by investing in innovative startups that utilize cutting-edge technologies and novel business models. The collaboration with Aetion aligns perfectly with NEC’s long-term goal of contributing to personalized medicine through RWD/RWE-based medical decision support. Such strategic investments underscore NEC’s commitment to driving advancements in the healthcare sector and fostering innovation that can drastically improve patient outcomes.
Leadership Perspectives
Corporate Senior Vice President of NEC Corporation, Shigeki Wada, emphasized that the partnership with Aetion is a significant stride towards enhancing their efforts to create new social value and establish next-generation healthcare systems. According to Wada, this collaboration represents a strategic move to leverage data for improved drug development processes, ultimately benefiting patients worldwide through more accurate and personalized treatments.
On the other hand, Jeremy Rassen, Chief Executive Officer and Co-founder of Aetion, expressed optimism about the continued partnership with NEC. He highlighted that the investment from NEC Orchestrating Future Fund reflects their shared vision of utilizing Aetion’s software to aid decision-makers on a global scale. Rassen believes that this collaboration will drive significant changes across the healthcare landscape, addressing the growing demand for decision-grade solutions that can enhance clinical and regulatory decisions.
NEC’s Commitment to Innovation
NEC Orchestrating Future Fund has made a significant investment in Aetion, a U.S.-based company that provides healthcare analytics platforms. This partnership is geared towards enhancing the Real World Data (RWD) and Real World Evidence (RWE) business, especially in the realm of drug development. The primary goal of this collaboration is to address the urgent need for evaluating the safety and effectiveness of drugs through comprehensive and large-scale data analysis. As the demand for effective medical interventions continues to rise, utilizing RWD and RWE is essential for closing the gap between clinical trials and real-world applications. By leveraging vast amounts of real-world data, NEC and Aetion aim to ensure that medications are not only clinically tested but also proven effective and safe in everyday settings. This endeavor is poised to revolutionize the way pharmaceutical companies approach drug development, leading to more robust and reliable medical treatments that can better serve global health needs.
